Cannabinoids are a group of molecules that interact with the receptors of the endocannabinoid system. They are referred to as endocannabinoids if they occur in our body as part of physiological processes. They are called phytocannabinoides when they are of plant origin and synthetic cannabinoids when they have been created artificially in a laboratory.

In the beginning, the term cannabinoid was linked to the compounds of cannabis itself. Now, the cannabinoid concept is given to all the chemicals that interact with cannabinoid receptors.

Usually, the study of cannabinoids has focused on the human endocannabinoid system but, taking into account its mechanisms of action and the therapeutic possibilities that they offer, researchers have also begun to study the animal endocannabinoid system.

medical cannabis uk | Kalapa Clinic



Endocannabinoids are molecules produced by our bodies that act as messengers through cannabinoid receptors. The most important are anandamide (SAA) and 2-Araquidonil-glycerol (2-AG), as both are synthesized on demand (endocannabinoids are not stored in the body, but are synthesized on demand where and when the body requires them to function). Moreover, they act on their respective receptors and are degraded through the FAAH enzyme, all in the same place of action. They do not act in a systemic way, ie, they only act in the exact location of our body where a specific and selective effect is needed, depending on the type of cell in which the endocannabinoid receptors are activated.

In recent years, knowledge about the implications of cannabinoids on different physiological systems has increased significantly. It is also known that the endocannabinoid system can influence the three basic systems of physiological regulation: the neurotransmitter system, the immune system, and the endocrine system.


Cannabis Oil UK | Cannabinoids | Kalapa Clinic

Phytocannabinoids of Cannabis

The varieties of the Cannabis plant contain about 500 different chemical compounds, of which one hundred, approximately, are part of the phytocannabinoids family (Waseem, 2014). The most studied cannabinoids, from a therapeutic point of view, are delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD), although researchers are beginning to investigate into cannabinoids such as Cannabinol (CBN), Tetrahydrocannabivarin (THCV) and Cannabigerol (CBG), as they are showing characteristics of potential medical interest in different pre-clinical studies.

When cannabinoids are in the plant they are in their acidic form. In this state, THC, for example, has no psychoactive effect. With the application of heat it undergoes the process of decarboxylation and it passes into its active form, which has psychoactive properties.

Apart from the cannabinoids contained in the plant, there are other chemical compounds with therapeutic potential. Particularly noteworthy are the terpenoids, which are an attributed part of the organoleptic properties of Cannabis (McPartland et al., 2014). There are also other families of compounds that have not been studied yet such as flavonoids, alkaloids, phytosterols, etc.

The Entourage Effect of Cannabinoids 

The presence of such a high quantity of different compounds in the cannabis plant can result in pharmacological interactions, either synergistically or antagonistically. While studying these interactions it has been observed that, both in terms of efficacy and tolerability, treatments with complete preparations of the plant have been more promising than the use of isolated cannabinoids. This effect, called the “Entourage” effect, was first described by Raphael Mechoulam in 1998 (Ben-Shabbat, 1998; Russo and Taming, 2011). The best example described so far is the THC-CBD pair whose combination makes THC better distributed, increases bioavailability (our body uses the available amount in the most efficient way) and reduces possible side effects ( McPartland et al., 2014). Although there are few studies on the subject, it is believed that the entourage effect is not due only to interactions between the different phytocannabinoides, but also due to the functional interaction between cannabinoids and non-cannabinoid components of the plant, like the terpenes and flavonoids.

There are several therapeutic qualities of phytocannabinoids that have been discovered. These types of cannabinoids are metabolized in the receptors CB1 and CB2, and are useful in conditions with chronic pain and/or inflammatory processes.
Cannabis Oil UK | Cannabinoids | Kalapa Clinic


Synthetic Cannabinoids

Synthetic cannabinoids are generated, as the name suggests, artificially, taking in to account the qualities of the endocannabinoids and phytocannabinoids.

They are extracts made in laboratories and are copies of the most relevant characteristics of endocannabinoids, so they work and are metabolized in receptors CB1 and CB2 but they do not have the same effects as phytocannabinoides or endocannabinoids and do not have pharmacological effects as potent as those of THC (Mechoulam, 2016).

The first synthetic cannabinoids were discovered in the 1970’s in order to explore and understand the pathways of the endogenous cannabinoid system.

Some synthetic cannabinoids, such as Dronabinol and Nabilone, are used at a medical level to treat nausea and vomiting caused by treatment with chemotherapy or in cases of anorexia caused by immunodeficiency’s due to their orexigenic properties.

Only phytocannabinoids are metabolised in the same receptors (CB1 and CB2) in the endocannabinoid system.


Bibliography for Cannabinoids

El Sohly M, Waseeem G. Constituents of Cannabis Sativa. In: Pertwee RG, editor. Handbook of Cannabis. Oxford, United Kingdom: Oxford University Press; 2014. p. 3-22.

Ben-Shabat S, Fride E, Sheskin T, Tamiri T, y cols. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2- arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353(1):23-31.

Russo EB. Taming THC: potential cannabis synergy and phytocanna- binoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-64.

McPartland JM, Russo EB. Non-Phytocannabinoid Constituents of Cannabis and Herbal Synergy. In: Pertwee RG, editor. Hand- book of Cannabis. Oxford, United Kingdom: Oxford University Press; 2014. p. 280-95.

Mechoulam R. Cannabis – the Israeli perspective. J Basic Clin Physiol Pharmacol. 2016, 27(3):181-187


  • arthritis-l'arthrite-l'osteoartrite-artritis

The use of medical Cannabis to treat osteoarthritis and arthritis

20,02, 2019|Comments Off on The use of medical Cannabis to treat osteoarthritis and arthritis

Osteoarthritis or chronic degenerative arthropathy is a degeneration of the cartilage of the joints without inflammation or infection. In the joint, the cartilage cracks and disappears, this is followed by bone growths that interfere with [...]

  • fibrosis quistica-Mukoviszidose-fibrose kystique-fibrosi cistica-cystic fibrosis

Can medical cannabis help patients with cystic fibrosis?

13,02, 2019|Comments Off on Can medical cannabis help patients with cystic fibrosis?

Cystic fibrosis is an inherited and fatal metabolic disease. It is caused by the presence of mutations in the genes responsible for salt and water transportation in the cells. This abnormal or undesired condition produces [...]

  • Ehlers-Danlos-Syndrom Ehlers-Danlos Syndrome

Symptom management for Ehlers-Danlos Syndrome

03,02, 2019|Comments Off on Symptom management for Ehlers-Danlos Syndrome

Ehlers-Danlos Syndromes (EDS) are a group of hereditary genetic conditions that affect the connective tissue in the human body. These cellular organizational level, support our bones, skin, blood and multiple other organs. Ehlers-Danlos Syndrome: symptoms [...]

  • cannabis medicinal en Reino Unido-medical cannabis-medizinischem Cannabis-cannabis medica in uk

Legal Framework in the UK regarding use of Medical Cannabis

31,01, 2019|Comments Off on Legal Framework in the UK regarding use of Medical Cannabis

During the last year 2018, the legislation surrounding therapeutic Cannabis in the UK was in constant change, due to the need to help patients suffering from severe intractable epilepsy. Besides, Canada became the second country [...]

No votes yet.
Please wait...